Sonia Resik

TL;DR: This large-scale evaluation demonstrates the feasibility of fractional doses of IPV given intradermally as an antigen-sparing strategy but also shows that IPv given to infants at 6, 10, and 14 weeks of age results in suboptimal immunogenicity (especially for the fractional-dose arm).

TL;DR: This evaluation shows that vaccinating infants with a single fractional dose of IPV can induce priming and seroconversion in more than 90% of immunized infants.

TL;DR: A phase I clinical trial was performed to examine the safety and immunogenicity of a multi-epitope polypeptide comprising the central 15 amino acids of the V3 loop from six HIV-1 isolates, and strong local reactions were observed.

TL;DR: One of the two newly developed intradermal-only jet injectors demonstrated its ability to streamline intradermally fIPV administration, however, further investigations are needed to assess the potential contribution of fIPv in the polio endgame plan.

TL;DR: This work has used retrospective samples to examine two HIV-1 transmission networks established by contact tracing and found only a subset of the tested sequence clusters was consistent with the reported epidemiological linkage.